Cancer in dogs

Is your pet exposed to secondhand smoke? Here are the (serious) health risks

Retrieved on: 
Tuesday, February 6, 2024
Smoke, Cancer in dogs, Genetics, Breast, Human, Heart, Bird, Environment, Food, Smoking, Dog, Incidence, Longevity, Lymphoma, Collie, Lung cancer, Diet, Rabbit, Ventilation, Air pollution, Dentistry, Filter (signal processing), Water, Nicotine, Tobacco, Risk, Education, Smoker, Death, Cat, Bladder cancer, Health, Bed, Cancer, Pet, Pollutant

Between 80 and 90% of lung cancer cases are associated with exposure to cancer-causing componds from first-or second-hand smoking.

Key Points: 
  • Between 80 and 90% of lung cancer cases are associated with exposure to cancer-causing componds from first-or second-hand smoking.
  • Children’s oral health, development, and future health outcomes are also negatively affected by exposure to secondhand smoke.
  • Exposure to secondhand smoke is a common but avoidable risk factor for health concerns in pets and people alike.
  • Reducing exposure to secondhand smoke, can enhance overall health, welfare and longevity for both pets and their people.

St. Baldrick's Works to Give Kids with Cancer More Than Five Years

Retrieved on: 
Tuesday, June 15, 2021
Cancer, Pediatric cancers, Health, Neoplasms, Oncology, Cancer in cats, Cancer in dogs, Osteosarcoma, Sarcoma, Bone tumor, Childhood cancer, Breast cancer

But, according to the National Cancer Institute, the five-year survival rate for childhood cancers has risen to 84% overall.

Key Points: 
  • But, according to the National Cancer Institute, the five-year survival rate for childhood cancers has risen to 84% overall.
  • That is meaningful in scientific terms, but it's just not good enough for a child with cancer.
  • While hitting the five-year milestone is worth celebrating, some will die later, either of their cancer or the effects of their treatment.
  • But, for other types of childhood cancer like osteosarcoma, a cancer of the bone treatment is not much different today than it was decades ago.

Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma

Retrieved on: 
Tuesday, March 9, 2021
Medical specialties, Sarcoma, Cancer in cats, Cancer in dogs, Osteosarcoma, Organ systems, Anatomy, Anatomical pathology, Programmed cell death protein 1, Bone tumor

Hrsholm, Denmark (9 March 2021) Allarity Therapeutics A/S (Allarity or the Company) today announced positive data from its preclinical assessment of dovitinibs antitumor activity in osteosarcoma, the most common primary malignant bone tumor in children and young adults.

Key Points: 
  • Hrsholm, Denmark (9 March 2021) Allarity Therapeutics A/S (Allarity or the Company) today announced positive data from its preclinical assessment of dovitinibs antitumor activity in osteosarcoma, the most common primary malignant bone tumor in children and young adults.
  • Furthermore, the combination of dovitinib and anti-PD-1 antibody did not generate additive or synergistic antitumor activities equal or greater than observed by dovitinib alone in the mouse osteosarcoma model.
  • Allarity Therapeutics has chosen osteosarcoma as the pediatric indication in which to evaluate the efficacy and safety of dovitinib on the basis of the reported preclinical study.
  • A positive preclinical assessment, as announced today, is a part of the normal prerequisites for initiating a clinical trial in pediatric patients with osteosarcoma.

Radius Health, Inc. Provides Abaloparatide Business Update

Retrieved on: 
Friday, February 12, 2021
Abaloparatide, Cancer in cats, Cancer in dogs, Osteosarcoma, Medical specialties, Anatomical pathology, Clinical medicine, Bone tumor, Sarcoma, Branches of biology

17% growth in January 2021 for new TYMLOS patients vs. previous 4 month trailing average

Key Points: 
  • 17% growth in January 2021 for new TYMLOS patients vs. previous 4 month trailing average
    BOSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc.(Radius or the Company) (Nasdaq: RDUS) provided a business update on the abaloparatide global business.
  • We expect continued new patient growth with our U.S. TYMLOS business.
  • Abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma (a malignant bone tumor) in male and female rats.
  • Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine and other therapeutics.

Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies

Retrieved on: 
Tuesday, January 19, 2021
Cancer in cats, Cancer in dogs, Osteosarcoma, Sarcoma, Cancer, Neoplasms, Health

OS Therapies secured funding to support this research, triggering the first milestone payment.

Key Points: 
  • OS Therapies secured funding to support this research, triggering the first milestone payment.
  • Under the agreement, Advaxis will receive additional clinical, regulatory, and sales-based milestone payments as well as royalties on future product sales.
  • We are pleased that OS Therapies is now in position to initiate human clinical trials of OST-HER2 in osteosarcoma, said Kenneth A. Berlin, President and Chief Executive Officer of Advaxis.
  • Paul Romness, Chief Executive Officer of OS Therapies, said, The OS Therapies mission is to develop and commercialize new therapeutics for the treatment of osteosarcoma, a deadly and extremely underserved pediatric cancer.

Osteosarcoma Epidemiology Report 2020: In-depth Understanding, Historical and Forecasted Epidemiology Data 2017-2030

Retrieved on: 
Tuesday, January 12, 2021
Pediatric cancers, Sarcoma, Cancer in cats, Cancer in dogs, Osteosarcoma, Anatomical pathology, Cancer, Neoplasms, Medical specialties

This 'Osteosarcoma - Epidemiology Forecast-2030' report delivers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Key Points: 
  • This 'Osteosarcoma - Epidemiology Forecast-2030' report delivers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Osteosarcoma, Gender-specific Incident Cases of Osteosarcoma, Age-specific Incident Cases of Osteosarcoma, Stage-specific Incident Cases of Osteosarcoma, Sub-types specific Incident Cases of Osteosarcoma, and Site-specific Incident Cases of Osteosarcoma scenario of Osteosarcoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
  • As per the publisher's estimates, the Incident cases of Osteosarcoma in the 7MM were 2,181 cases in 2017 during the study period (2017-2030).
  • In the US, Conventional osteosarcoma accounted for nearly 80% of total osteosarcoma cases.

FDA Conditionally Approves First Oral Tablet to Treat Lymphoma in Dogs

Retrieved on: 
Monday, January 11, 2021
Medical specialties, Branches of biology, Medicine, Lymphoma, Cancer in dogs, Cancer in cats, Lymphoma in animals, Lymphadenopathy

Laverdia-CA1 is the first conditionally approved oral treatment for dogs with lymphoma.

Key Points: 
  • Laverdia-CA1 is the first conditionally approved oral treatment for dogs with lymphoma.
  • This conditional approval provides a much-needed option to treat dogs with lymphoma," said Steven M. Solomon, D.V.M., M.P.H., director of the FDA's Center for Veterinary Medicine.
  • The study included dogs of varying breeds, weights and both genders, with the majority of the dogs having lymphoma stage III (generalized lymph node enlargement).
  • Canine lymphoma affects fewer than 70,000 dogs in the U.S. each year, and therefore, qualifies as a minor use in a major species.

MIB Agents Accepting Proposals for $100,000 Outsmarting Osteosarcoma Research Grant

Retrieved on: 
Monday, January 11, 2021
Medicine, Clinical medicine, Medical specialties, Pediatric cancers, Sarcoma, Cancer in cats, Cancer in dogs, Osteosarcoma, Neutering

BARNARD, Vt., Jan. 11, 2021 /PRNewswire/ -- MIB Agents , a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, caregivers, doctors and researchers, is accepting proposals for its annual $100,000 OutSmarting Osteosarcoma research grant .

Key Points: 
  • BARNARD, Vt., Jan. 11, 2021 /PRNewswire/ -- MIB Agents , a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, caregivers, doctors and researchers, is accepting proposals for its annual $100,000 OutSmarting Osteosarcoma research grant .
  • This grant was established in 2017 and is awarded to a project focused on moving research forward for osteosarcoma patients.
  • MIB Agents, a pediatric cancer nonprofit, is accepting proposals for its OutSmarting Osteosarcoma research grant.
  • The OutSmarting Osteosarcoma Grant is reviewed and juried by members of the entire osteosarcoma community- scientists, physicians, patients and families.

Osteosarcoma Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 11, 2021
Health, Oncology, Pediatric cancers, Sarcoma, Cancer in cats, Cancer in dogs, Osteosarcoma, Anatomical pathology, Cancer, Neoplasms, Medical specialties

The "Osteosarcoma - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Osteosarcoma - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Osteosarcoma - Epidemiology Forecast-2030' report delivers an in-depth understanding of the Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Osteosarcoma, Gender-specific Incident Cases of Osteosarcoma, Age-specific Incident Cases of Osteosarcoma, Stage-specific Incident Cases of Osteosarcoma, Sub-types specific Incident Cases of Osteosarcoma, and Site-specific Incident Cases of Osteosarcoma scenario of Osteosarcoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
  • In the US, Conventional osteosarcoma accounted for nearly 80% of total osteosarcoma cases.

Y-mAbs Announces Pipeline Update

Retrieved on: 
Wednesday, December 16, 2020
Pediatric cancers, Cancer in cats, Cancer in dogs, Osteosarcoma, Sarcoma, Anatomical pathology, Survival rate, Cancer, Medical specialties, Branches of biology

Patients in first CR showed an overall 74.3% event free survival (EFS) at 24 months and an overall survival (OS) of 91.6% at 24 months.

Key Points: 
  • Patients in first CR showed an overall 74.3% event free survival (EFS) at 24 months and an overall survival (OS) of 91.6% at 24 months.
  • Patients in second CR showed an overall 38.5% EFS at 24 months and an OS of 88.1% at 24 months.
  • In osteosarcoma, the Company will present an update on its ongoing Phase 2 study, which started more than 4 years ago at MSK and has now been approved for recruitment at two other U.S. sites.
  • Dr. Claus Moller, Chief Executive Officer further notes, We are excited to share this broad update on our pipeline and believe this to be class leading clinical results.